SOUTH SAN FRANCISCO, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Anesiva, Inc. will announce financial results for the second quarter 2006 after the markets close on Wednesday, August 9, 2006 and will hold a webcast teleconference at 4:30 p.m. EDT that day. Members of Anesiva’s management team will discuss financial results from the second quarter and six months ended June 30, 2006, as well as provide an overview of the company’s product pipeline, recent events and milestones for 2006.
Interested parties can listen to the live audio webcast by dialing 800-340-6289 (international dial: 706-634-1538) or by logging on to www.anesiva.com and going to the Investor Information page. Please connect to Anesiva’s website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary. For those unable to listen to the live conference call or to access the call via the internet, a 24-hour dial-in replay will be available for seven days after the call by dialing 800-642-1687 (international dial: 706-645-9291) and giving the following pass code: 3768021. The webcast will be available on the Anesiva website until the company’s next quarterly financial results conference call.
About Anesiva and its Diverse Pipeline of Pain Products
Anesiva, Inc., formerly Corgentech Inc., is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has three drug candidates in development for multiple pain-related indications, the most advanced of which, 3268, has completed Phase 3 clinical trials. The second product in the pipeline, 4975, has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. 1207, a new local anesthetic that is undergoing preclinical development as a topical local anesthetic, is anticipated to enter the clinic in 2006. Anesiva is based in South San Francisco, CA. For more information about Anesiva’s leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to www.anesiva.com.
Anesiva, Inc.
CONTACT: Jennifer Cook Williams, Vice President, Investor Relations ofAnesiva, +1-650-624-9600, or investors@anesiva.com
Web site: http://www.anesiva.com//
